Mass exodus in MS

Quote
Novartis MS division is ruining access for all MS company's. I work for a smaller company in the MS space. I had a speaker with me that works for a very open access great MS clinic outside my territory. She told me the clinic is thinking about restricting access and putting rules in place because of Novartis. I guess 3 different reps had appt's and lunch's within two days! She said it is too much. Please don't ruin access for all us. Neurologists are already one of the toughest specialties to access.
 






Anonymous said:
Novartis MS division is ruining access for all MS company's. I work for a smaller company in the MS space. I had a speaker with me that works for a very open access great MS clinic outside my territory. She told me the clinic is thinking about restricting access and putting rules in place because of Novartis. I guess 3 different reps had appt's and lunch's within two days! She said it is too much. Please don't ruin access for all us. Neurologists are already one of the toughest specialties to access.
Click to expand...

Reach and frequency is more important than clinical knowledge. We are still in the primary care philosophy. $48k per patient and they are nickel and diming the reps with bonus.

Management open your minds for a moment. You pay us $4500 per quarter instead of $7500. You save $3000. $3000 vs. $48k per patient. You are losing patient after patient for $3000 per quarter. Is that a good business decision?
 






Anonymous said:
Reach and frequency is more important than clinical knowledge. We are still in the primary care philosophy. $48k per patient and they are nickel and diming the reps with bonus.

Management open your minds for a moment. You pay us $4500 per quarter instead of $7500. You save $3000. $3000 vs. $48k per patient. You are losing patient after patient for $3000 per quarter. Is that a good business decision?
Click to expand...

This company can get away with it. All your efforts are subjective. Besides, job opportunities are limited out there and the company knows that, and you won't be going anywhere
 






Anonymous said:
This company can get away with it. All your efforts are subjective. Besides, job opportunities are limited out there and the company knows that, and you won't be going anywhere
Click to expand...

The point is they are not maximizing the amount of patients because of the disgruntled rep. It has nothing to do with leaving it comes down to the rep making the extra effort or becoming lazy because the payout is not worth the effort.
 






Anonymous said:
Novartis upper management has no idea what is to come when Buyogen launches BG12. They will see a company launch an oral with comparative marketing materials right out of the gate and a sales team that will stop at nothing to get business. Novartis MS newbies are about to get a rude awakening to the hostile MS market place. Bet you that Buy O Gen has more marketing info, data, etc. before Gilenya does....and we had a 1 year head start. I was around for Avonex and Tysabri launches and can tell you that the Gilenya launch has no comparisons. Buyogen would have fired the marketing team and upper management.[/they should fire all upper ms managements , all the reps who came from fucking biogen, they still are working for that company , bastered take a hick.QUOTE]
Click to expand...
 






they should fire all ms management, the idiots are running in a circle. also fire all fuck up reps from biogen they think they are still working for biogen hoping to go back soon, the bastered are betraying novartis and laughing all the way to the bank.
 


















Im enjoying watching ex-avonex reps wonder why their loyal avonex customers will not prescribe Gilenya. It's harder to sell when you're company is not buying the business.
 






Top Bottom
Back
Quote